Guillermo Arreaza-Rubin, MD
NIDDK/NIH, Bethesda, Maryland

As director for clinical immunology of diabetes program and the technologies for the diagnosis and diabetes control program, I oversee a variety of research projects designed to improve diagnosis, treatment and monitoring of this disease.  My responsibilities include directing the Small Business Innovation Research/Small Business Technology Transfer Research (SBIR/STTR) program—which supports innovative research by small businesses that have the potential for commercialization—in areas related to immunology, diabetes, and other endocrine and metabolic diseases.  These areas include:  drug discovery for diabetes and other endocrine diseases; new technologies for islet isolation, stem cell/regeneration, and transplantation; immune modulatory agents for the primary and secondary prevention of diabetes; inflammatory aspects of type 2 diabetes, insulin resistance, and obesity; and diabetes control and management technologies.  I oversee academic research on closed-loop systems/artificial pancreas development/testing including novel glucose/metabolite sensors, integrated pancreatic hormone replacement delivery technologies and novel cell therapies.  My duties also include being program director for the Clinical Islet Transplantation (CIT) Consortium and the Clinical Islet Transplant Registry (CITR) acting as the executive secretary of the Clinical Islet Transplantation Consortium Data and Safety Monitoring Board.  I also participate in the coordination of the new human islet research network (HIRN) program as a program director for the consortium for modeling autoimmunity (CMAI), the consortium on human islet biomimetics (CHIB) and represent the NIDDK on several trans-NIH and interagency working groups on metabolic monitoring, inflammatory processes, autoimmunity and medical devices development and performance surveillance.